Geneseeq, Author at Geneseeq Technology Inc. | A Precision Oncology Company - Page 2 of 2

August 31, 2021

Geneseeq Study Evaluates ctDNA MRD to Predict Response to Therapy and Assess Prognosis in Locally Advanced Rectal Cancer

0 Comments3 Minutes

June 24, 2021

Geneseeq works with HUTCHMED and AstraZeneca in MET inhibitor approval for lung cancer patients in China

0 Comments2 Minutes

June 17, 2021

Geneseeq Joins Integrated DNA Technologies (IDT) Align Program

0 Comments5 Minutes

May 26, 2021

Geneseeq Presenting Data at the American Society of Clinical Oncology Annual Meeting 2021

0 Comments9 Minutes

May 18, 2021

Geneseeq study shows ctDNA evaluation in early postoperative phase predicts risk of recurrence in colorectal cancer

0 Comments3 Minutes

April 27, 2021

Geneseeq and AstraZeneca Collaborate to Build Guangzhou Bio-Diagnostics Innovation Center

0 Comments4 Minutes

April 9, 2021

Geneseeq to Present at American Association for Cancer Research Annual Meeting 2021

0 Comments10 Minutes

March 25, 2021

Genomic Study Uncovers New Biomarkers for the Efficacy of Immunotherapy in Nasopharyngeal Carcinoma (NPC) Patients

0 Comments2 Minutes

March 19, 2021

Lung cancer genomic study reveals timing and origins of local and distant metastases and highlights the importance of early cancer detection

0 Comments3 Minutes

March 16, 2021

Geneseeq Collaborates with Illumina to Develop and Commercialize Comprehensive Cancer In-vitro Diagnostic NGS kit

0 Comments4 Minutes